SG Americas Securities LLC Has $574,000 Holdings in CareDx, Inc (NASDAQ:CDNA)

SG Americas Securities LLC trimmed its stake in CareDx, Inc (NASDAQ:CDNA - Free Report) by 83.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,381 shares of the company's stock after selling 92,035 shares during the quarter. SG Americas Securities LLC's holdings in CareDx were worth $574,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in CDNA. Caxton Associates LP grew its stake in CareDx by 97.2% in the first quarter. Caxton Associates LP now owns 96,308 shares of the company's stock valued at $1,020,000 after purchasing an additional 47,469 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in CareDx by 87.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 228,198 shares of the company's stock worth $2,417,000 after buying an additional 106,660 shares during the last quarter. Renaissance Technologies LLC raised its position in CareDx by 6.2% during the second quarter. Renaissance Technologies LLC now owns 1,512,700 shares of the company's stock valued at $23,492,000 after acquiring an additional 88,100 shares in the last quarter. Bamco Inc. NY bought a new position in CareDx during the first quarter valued at approximately $13,025,000. Finally, Vanguard Group Inc. lifted its stake in CareDx by 4.4% in the first quarter. Vanguard Group Inc. now owns 4,300,016 shares of the company's stock valued at $45,537,000 after acquiring an additional 180,334 shares during the last quarter.

Analysts Set New Price Targets

CDNA has been the topic of several analyst reports. StockNews.com lowered shares of CareDx from a "buy" rating to a "hold" rating in a research note on Wednesday, October 2nd. Craig Hallum raised their target price on CareDx from $22.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, August 1st. The Goldman Sachs Group increased their price objective on CareDx from $16.00 to $26.00 and gave the company a "buy" rating in a report on Thursday, August 1st. Wells Fargo & Company began coverage on CareDx in a report on Tuesday, August 27th. They issued an "underweight" rating and a $28.00 target price for the company. Finally, BTIG Research upgraded CareDx from a "neutral" rating to a "buy" rating and set a $40.00 price target on the stock in a report on Monday, August 19th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $28.80.

CareDx Stock Down 15.8 %

NASDAQ CDNA traded down $4.96 during trading on Tuesday, hitting $26.35. The company's stock had a trading volume of 2,121,760 shares, compared to its average volume of 903,582. CareDx, Inc has a 52 week low of $4.80 and a 52 week high of $34.84. The firm has a 50 day moving average price of $29.67 and a 200 day moving average price of $19.36. The firm has a market cap of $1.37 billion, a P/E ratio of -7.97 and a beta of 1.77.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.37. The company had revenue of $92.27 million for the quarter, compared to analyst estimates of $67.20 million. CareDx had a negative net margin of 53.73% and a negative return on equity of 53.65%. On average, equities analysts expect that CareDx, Inc will post -0.84 earnings per share for the current year.

Insider Activity at CareDx

In other CareDx news, insider Alexander L. Johnson sold 34,231 shares of the firm's stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $33.55, for a total value of $1,148,450.05. Following the completion of the sale, the insider now owns 284,983 shares in the company, valued at approximately $9,561,179.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other CareDx news, Director Peter Maag sold 35,552 shares of the business's stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $33.04, for a total value of $1,174,638.08. Following the sale, the director now owns 330,024 shares of the company's stock, valued at $10,903,992.96. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Alexander L. Johnson sold 34,231 shares of the stock in a transaction on Monday, August 19th. The shares were sold at an average price of $33.55, for a total transaction of $1,148,450.05. Following the completion of the transaction, the insider now owns 284,983 shares of the company's stock, valued at approximately $9,561,179.65. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 91,340 shares of company stock worth $3,025,415 over the last three months. Company insiders own 4.20% of the company's stock.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.